The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics
Open accessAbstract
As clinical applications for chimeric antigen receptor T cell (CART) therapy extend beyond early phase trials, commercial manufacture incorporating cryopreservation steps becomes a logistical necessity. The effect of cryopreservation on CART characteristics is unclear. We retrospectively evaluated the effect of cryopreservation on product release criteria and in vivo characteristics in 158 autologous CART products from 6 single-center clinical trials. Further, from 3 healthy donor manufacturing runs, we prospectively identified differentially expressed cell surface markers and gene signatures among fresh versus cryopreserved CARTs. Within 2 days of culture initiation, cell viability of the starting fraction (peripheral blood mononuclear cells [PBMNCs]) decreased significantly in the cryo-thawed arm compared to the fresh arm. Despite this, PBMNC cryopreservation did not affect final CART fold expansion, transduction efficiency, CD3%, or CD4:CD8 ratios. In vivo CART persistence and clinical responses did not differ among fresh and cryopreserved final products. In healthy donors, compared to fresh CARTs, early apoptotic cell-surface markers were significantly elevated in cryo-thawed CARTs. Cryo-thawed CARTs also demonstrated significantly elevated expression of mitochondrial dysfunction, apoptosis signaling, and cell cycle damage pathways. Cryopreservation during CART manufacture is a viable strategy, based on standard product release parameters. The clinical impact of cryopreservation-related subtle micro-cellular damage needs further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“POC manufacturing enables the delivery of fresh CAR-T cells, which were shown earlier to have higher in vitro antitumor activity and lesser microcellular damage than the frozen,4,5”
From Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, Panch et al. showed recovery and viability of PBMCs was significantly reduced after freezing and thawing compared to fresh apheresis products (39). Nevertheless, the recovery of mononuclear cells after thawing was sufficient for consistent manufacturing of CAR T cells, without evidence of significant differences in expansion, transduction efficiency or overall subset composition (39)”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Self-citationClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,363
Self-citationAli, S. A., Shi, V., Marić, I., Wang, M. L., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler‐Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 776
Self-citationRuella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659
Self-citationClinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Brudno, J. N., Somerville, R. P. T., Shi, V. J., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea‐Banacloche, J., Pavletic, S. Z., Hickstein, D. D., Lu, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605
Self-citationA guide to manufacturing CAR T cell therapies
Vormittag, P., Gunn, R., Ghorashian, S., & Veraitch, F. S. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.01.025 · Cited by 403
Cited by
Sorted by citations
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1081-3 · Cited by 468
Self-citationChemical approaches to cryopreservation
Murray, K. A., & Gibson, M. I. (2022) · Nature Reviews Chemistry · doi:10.1038/s41570-022-00407-4 · Cited by 400
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Amini, L., Silbert, S. K., Maude, S. L., Nastoupil, L. J., Ramos, C. A., Brentjens, R. J., Sauter, C. S., Shah, N. N., & Abou‐El‐Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00607-3 · Cited by 347
Self-citationScalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321
Impact of Manufacturing Procedures on CAR T Cell Functionality
Watanabe, N., Mo, F., & McKenna, M. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876339 · Cited by 206
Makkouk, A., Yang, X., Barca, T., Lucas, A., Turkoz, M., Wong, J. T. S., Nishimoto, K. P., Brodey, M. M., Tabrizizad, M., Gundurao, S. R. Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003441 · Cited by 199
Cottle, C., Porter, A. P., Lipat, A. J., Turner-Lyles, C., Nguyen, J., Moll, G., & Chinnadurai, R. (2022) · Current Stem Cell Reports · doi:10.1007/s40778-022-00212-1 · Cited by 153
Stock, S., Schmitt, M. W., & Sellner, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246223 · Cited by 146
Advances in NK cell production
Fang, F., Xie, S., Chen, M., Li, Y., Yue, J., Ma, J., Shu, X., He, Y., Xiao, W., & Tian, Z. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00808-3 · Cited by 132
Corti, C., Venetis, K., Sajjadi, E., Zattoni, L., Curigliano, G., & Fusco, N. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2054326 · Cited by 86
Dimethyl sulfoxide-free cryopreservation for cell therapy: A review
Weng, L., & Beauchesne, P. R. (2020) · Cryobiology · doi:10.1016/j.cryobiol.2020.03.012 · Cited by 85
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18
Glienke, W., Dragon, A. C., Zimmermann, K., Martyniszyn, A., Mertens, M., Abken, H., Rössig, C., Altvater, B., Aleksandrova, K., Arseniev, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.839783 · Cited by 79
Hiltensperger, M., & Krackhardt, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121030 · Cited by 79
Improving CAR T cell therapy by optimizing critical quality attributes
Reddy, O. L., Stroncek, D. F., & Panch, S. R. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.07.005 · Cited by 74
Self-citationLong-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients
Hurme, A., Jalkanen, P., Heroum, J., Liedes, O., Vara, S., Melin, M. M., Teräsjärvi, J. T., He, Q., Pöysti, S., Hänninen, A. L. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.869990 · Cited by 60
Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy
Yao, X., & Matosevic, S. (2021) · BioDrugs · doi:10.1007/s40259-021-00494-7 · Cited by 54
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Huang, S., Wang, X., Wang, Y., Wang, Y., Fang, C., Wang, Y., Chen, S., Chen, R., Lei, T., Zhang, Y., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01783-1 · Cited by 56
Cadiñanos-Garai, A., Flugel, C., Cheung, A., Jiang, E., Vaissié, A., & Abou‐El‐Enein, M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.006 · Cited by 52
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers
Gu, X., Zhang, Y., Zhou, W., Wang, F., Yan, F., Gao, H., & Wang, W. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00542-2 · Cited by 49
Impact of cryopreservation on CAR T production and clinical response
Brezinger-Dayan, K., Itzhaki, O., Melnichenko, J., Kubi, A., Zeltzer, L.-A., Jacoby, E., Avigdor, A., Shapira Frommer, R., & Besser, M. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1024362 · Cited by 44
Assessment and comparison of viability assays for cellular products
Cai, Y., Procházková, M., Kim, Y., Jiang, C., Ma, J., Moses, L., Martin, K., Pham, V., Zhang, N., Highfill, S. L., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.11.008 · Cited by 44
Self-citationLam, C., Meinert, E., Yang, A., & Cui, Z. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2020.08.007 · Cited by 42
Martínez‐Cibrián, N., Español‐Rego, M., Pascal, M., Delgado, J., & Ortiz‐Maldonado, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005457 · Cited by 38
Yi, J. S., Rosa‐Bray, M., Staats, J. S., Zakroysky, P., Chan, C. C. W., Russo, M. A., Dumbauld, C., White, S., Gierman, T. M., Weinhold, K. J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225512 · Cited by 36
Nada, M. H., Wang, H., Hussein, A. J., Tanaka, Y., & Morita, C. T. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1989789 · Cited by 35
Expanding CAR-T cell immunotherapy horizons through microfluidics
Kim, H., Kim, S., Lim, H., & Chung, A. J. (2024) · Lab on a Chip · doi:10.1039/d3lc00622k · Cited by 34
Fresh versus Frozen: Effects of Cryopreservation on CAR T Cells
Hanley, P. J. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.001 · Cited by 30
Pi, C., Hornberger, K., Dosa, P. I., & Hubel, A. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.01.013 · Cited by 30
CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
Gambella, M., Carlomagno, S., Raiola, A. M., Giannoni, L., Ghiggi, C., Setti, C., Giordano, C., Luchetti, S., Serio, A., Bo, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837457 · Cited by 32
Leukapheresis for CAR-T cell production and therapy
Pessach, I., & Nagler, A. (2023) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2023.103828 · Cited by 32
Advances in manufacturing chimeric antigen receptor immune cell therapies
Ramamurthy, A., Tommasi, A. M., & Saha, K. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01019-4 · Cited by 27
Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy
Bouziana, S. D., & Bouzianas, D. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103096 · Cited by 20
Luanpitpong, S., Klaihmon, P., Janan, M., Kungwankiattichai, S., Owattanapanich, W., Kunacheewa, C., Chanthateyanonth, S., Donsakul, N., U-pratya, Y., Warindpong, T., et al. (2024) · Molecular Therapy: Oncology · doi:10.1016/j.omton.2024.200889 · Cited by 17
“POC manufacturing enables the delivery of fresh CAR-T cells, which were shown earlier to have higher in vitro antitumor activity and lesser microcellular damage than the frozen, 4,5 although whether fresh products would provide better clinical outcomes remains to be determined.”
Dreyzin, A., Panch, S. R., Shalabi, H., Yates, B., Highfill, S. L., Jin, P., Stroncek, D. F., & Shah, N. N. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.12.004 · Cited by 19
Self-citationSu, T., Ying, Z., Lu, X., He, T., Song, Y., Wang, X., Ping, L., Xie, Y., Tu, M., Liu, G., et al. (2020) · Cryobiology · doi:10.1016/j.cryobiol.2020.07.009 · Cited by 17
CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production
Abraham-Miranda, J., Menges, M. A., Atkins, R. M., Mattie, M., Kanska, J. E., Turner, J. G., Hidalgo-Vargas, M. J., & Locke, F. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1007042 · Cited by 17
Gilfanova, R., Callegari, A., Childs, A., Yang, G., Luarca, M., Gutierrez, A. G., Medina, K. I., Mai, J., Hui, A. J., Kline, M. A., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01368-w · Cited by 15
Song, H. W., Benzaoui, M., Dwivedi, A., Underwood, S., Shao, L., Achar, S. R., Posarac, V., Remley, V. A., Procházková, M., Cai, Y., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101171 · Cited by 17
Self-citationCryopreservation of Immune Cells: Recent Progress and Challenges Ahead
Qi, K., Jia, D., Zhou, S., Zhang, K., Guan, F., Yao, M., & Sui, X. (2024) · Advanced Biology · doi:10.1002/adbi.202400201 · Cited by 15
The Past, Present, and Future of Clinically Applied Chimeric Antigen Receptor-T-Cell Therapy
Fujiwara, Y., Kato, T., Hasegawa, F., Sunahara, M., & Tsurumaki, Y. (2022) · Pharmaceuticals · doi:10.3390/ph15020207 · Cited by 16
Jandová, M., Stacey, G. N., Lánská, M., Gregor, J., Rozsívalová, P., Beková, L., Ducháčová, Z. W., Belada, D., Radocha, J., Měřička, P., et al. (2023) · Cryoletters · doi:10.54680/fr23310110112 · Cited by 13
Kao, C., Mills, J. A., Burke, C. J., Morse, B. A., & Marques, B. F. (2023) · Biology · doi:10.3390/biology12050677 · Cited by 13
Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
Park, C. H. (2021) · Cancers · doi:10.3390/cancers13133236 · Cited by 11
Kilbride, P., Meneghel, J., Creasey, G., Masoudzadeh, F., Drew, T., Creasey, H., Bloxham, D. M., Morris, G. J., & Jestice, K. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240310 · Cited by 12
From cold chain to ambient: Benefits, risks, and evidence across cell therapy logistics
Gostage, J., Domingo-Lopez, D., Tarpey, R., Duffy, G. P., & Levey, R. (2025) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2025.101613 · Cited by 12
Human Natural Killer Cells Cryopreserved without DMSO Sustain Robust Effector Responses
Das, S., Niemeyer, E., Leung, Z., Fritsch, T., & Matosevic, S. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00798 · Cited by 11
Grabarek, A., Jiskoot, W., Hawe, A., Pike‐Overzet, K., & Menzen, T. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.07.004 · Cited by 11
Dan, N., Shelake, S., Luo, W.-C., Rahman, M., Lu, J. X., Bogner, R. H., & Lü, X. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124694 · Cited by 11
Update on the current and future use of CAR‐T to treat multiple myeloma
Gahvari, Z. J., Brunner, M., Schmidt, T. M., & Callander, N. S. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14145 · Cited by 9
A Multi-objective Multi-type Facility Location Problem for the Delivery of Personalised Medicine
Avramescu, A., Allmendinger, R., & López‐Ibáñez, M. (2021) · Lecture notes in computer science · doi:10.1007/978-3-030-72699-7_25 · Cited by 9
Saini, K. S., Svane, I. M., Juan, M., Barlési, F., & André, F. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.020 · Cited by 9
Proline pre-conditioning of Jurkat cells improves recovery after cryopreservation
Murray, A., Kilbride, P., & Gibson, M. I. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00274h · Cited by 8
Pros and Cons of Cryopreserving Allogeneic Stem Cell Products
Valentini, C. G., Pellegrino, C., & Teofili, L. (2024) · Cells · doi:10.3390/cells13060552 · Cited by 8
Preservation and Storage of Cells for Therapy: Current Applications and Protocols
Acker, J. P., Bondarovych, M. O., Brunotte, R., Buriak, I. A., Fuller, B. J., Glasmacher, B., Goltsev, А., Gregor, J., Gryshkov, O., Herrity, K., et al. (2022) · Reference series in biomedical engineering · doi:10.1007/978-3-319-37076-7_68-1 · Cited by 9
Post-thaw application of ROCK-inhibitors increases cryopreserved T-cell yield
Gonzalez-Martinez, N., & Gibson, M. I. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00378g · Cited by 8
Wu, K.-L., Martinez-Paniagua, M. A., Reichel, K., Menon, P. S., Deo, S., Roysam, B., & Varadarajan, N. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad584 · Cited by 7
Freezing life within refractory, amorphous silicon dioxide
Guo, S., Brinker, C. J., & Zhu, W. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00173-6 · Cited by 7
Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico
Salazar‐Riojas, R., Alvarado‐Navarro, D. M., Chávez-Estrada, Y. O., Hernández-Navarro, A. K., Ake-Uc, M. B., Moncada-Saucedo, N. K., Jaime‐Pérez, J. C., Quezada-Ramírez, S. I., Rodríguez-Zúñiga, A. C., Gómez‐Almaguer, D., et al. (2025) · JCO Global Oncology · doi:10.1200/go-24-00581 · Cited by 9
Improving cell viability using counterflow centrifugal elutriation
Li, A., Barabadi, M., McDonald, H., Chan, S. T., Krause, M., Ooi, J. D., Kusuma, G. D., James, D., & Lim, R. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.01.008 · Cited by 8
Worel, N., Ljungman, P. T., Verheggen, I. C. M., Hoogenboom, J. D., Knelange, N. S., Eikema, D.-J., Sánchez‐Ortega, I., Riillo, C., Centorrino, I., Averbuch, D., et al. (2023) · Bone Marrow Transplantation · doi:10.1038/s41409-023-02099-w · Cited by 7
Liao, Y., Hsu, S., & Chiou, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042416 · Cited by 7
Eskandari, A., Leow, T. C., Rahman, M. B. A., & Oslan, S. N. (2024) · European Biophysics Journal · doi:10.1007/s00249-024-01719-7 · Cited by 5
Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy
Chelvaretnam, S., Mom, K. T., Palma, C., Pham, Q., Fitri, A., Bhuiyan, S., Shojaee, M., Asari, K., Rashid, H., Hinch, L., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052163 · Cited by 4
Developing patient-centric specifications for autologous chimeric antigen receptor T cell therapies
Zhang, T., Larson, R. P., Dave, K., Polson, N., & Zhang, H. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100328 · Cited by 4
Chang, Y. H., Fujimori, Y., Chen, C., Urabe, M., Karaki, T., Izumi, Y., Kaneko, K., & Mochiki, K. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00808-9 · Cited by 4
The effects of cryopreservation on PBMCs transcriptome profile
Li, X., Chen, Q., Higgins, J. M., Cook, K., Baseler, M., Imamichi, T., & Chang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690316 · Cited by 3
Self-citationBioinspired (Glyco)Polypeptides for Ice‐Control and Cell Cryopreservation
Yuan, L., Zhang, X., Ren, L., & Yuan, X. (2026) · Advanced Materials · doi:10.1002/adma.73464 · Cited by 4
Strategies for manufacturing cell therapy products aligned with patient needs
Guha, P., & Katz, S. C. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.11.003 · Cited by 3
Ngo, H. T., Dang, V. T., Nguyen, N. H.-T., Bui, A. N.-T., & Pham, P. V. (2022) · Cell and Tissue Banking · doi:10.1007/s10561-022-10022-8 · Cited by 4
Take a spin: Apheresis in the care of adult leukaemia patients
Ai, J. (2023) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2023.101467 · Cited by 3
A comprehensive analysis of the immune system in healthy Vietnamese people
Huynh, C. D., Nguyen, M. P., Ngo, D. T., Nguyen, X., Nguyen, D. T., Thi, H., Le, T. H., Hoang, M. D., Linh, L. K., Nguyen, K. Q., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30647 · Cited by 4
Santis, G. C. D., Langhi, D. M., Feitoza, A., Mendrone, A., Kutner, J. M., Covas, D. T., Couto, S. C. F., Cunha, R., Orellana, M. D., & Rizzo, S. R. C. P. (2021) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2021.09.005 · Cited by 3
Beyond conventional treatment: Novel cell therapies for systemic lupus erythematosus
Zarei‐Behjani, Z., Hosseinpouri, A., Fotoohi, M., Shafiee, A., & Asadi, D. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100308 · Cited by 2
Broadening CAR-T access: lessons from real-world implementation of talicabtagene autoleucel in India
Purwar, A., Jain, H., & Kumar, S. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100026 · Cited by 2
CAR-T cell therapy and its complications: Role of the pathologist in diagnosis
Sarami, I., & Medeiros, L. J. (2026) · Human Pathology · doi:10.1016/j.humpath.2026.106199 · Cited by 2
Huang, Z., Liu, W., Ma, T., Zhao, H., He, X., & Liu, B. (2022) · Biopreservation and Biobanking · doi:10.1089/bio.2022.0028 · Cited by 2
Leone, G., Baldini, V., Bramanti, S., Crocchiolo, R., Gattillo, S., Ermini, S., Giudice, V., Ferrero, I., Moscato, T., Milani, R., et al. (2023) · Blood transfusion · doi:10.2450/bloodtransfus.471 · Cited by 2
Malise, T. T. A., Nweke, E. E., Takundwa, M. M., Fru, P., & Raj, D. B. T. G. (2023) · Advances in experimental medicine and biology · doi:10.1007/5584_2023_775 · Cited by 2
Current Role of CAR-T Therapy in Haematological Care
Jandová, M., Lánská, M., Šýkorová, A., Gregor, J., Rozsívalová, P., Beková, L., Ducháčová, Z. W., Radocha, J., Stacey, G., Měřička, P., et al. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-97297-3_16 · Cited by 2
Influence of dimethyl sulfoxide on membrane fluidity under rapid supercooling
Sahu, S., Dutta, P., & Debnath, A. I. (2024) · The European Physical Journal Special Topics · doi:10.1140/epjs/s11734-024-01296-y · Cited by 2
Zhou, Y. Y., & Maitta, R. W. (2025) · Regenerative medicine reports . · doi:10.4103/regenmed.regenmed-d-25-00012 · Cited by 1
Kuznetsova, D. V., & Petrova, T. V. (2025) · Acta Naturae · doi:10.32607/actanaturae.27559 · Cited by 1
Sarko, L. E., Givand, D., Rattin, B., Shepley, C., Tommasi, A., Attar, A., Taylor, R., Kutler, B., Traynor, R. M., Upadhyaya, A., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.029 · Cited by 1
Vasu, S., Denlinger, N., Song, N., Elsberry, D., Zhao, Q., Yu, L., Bezerra, E. D., Szuminski, N., Schneider, D., Dash, P., et al. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-26-0186 · Cited by 1
Self-citationNasiri, A. M., Fakih, R. O. E., Chabannon, C., Garderet, L., Kuball, J. H. E., Bazarbachi, A. A., Sureda, A. M., Lima, M. J. G. D., Abid, M. B., Syed, F., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-03044-3 · Cited by 1
Conception and Configuration of Biobank of CART Biospecimen Sets for Pediatrics Research
Wang, M., Li, S., & Zhou, J. (2023) · Innovations in Digital Health Diagnostics and Biomarkers · doi:10.36401/iddb-22-8 · Cited by 1
Manufacturing of CAR-T Cells: The Assembly Line
Wang, X., & Rivière, I. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_8 · Cited by 1
Sonnenfeld, T., Rauchbach, E., Downey, R., Blumenkrants, D., Kuperstein, G., Kronfeld, N., Margalit, R., Morad, V., Nyska, A., Slutsky, S. G., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2719747/v1 · Cited by 1
Establishment of a New Cryopreservation Solution for Chimeric Antigen Receptor T Cells
Tang, Q., Gu, L., Zhou, B., Shi, J., Wu, H., Zhu, H., Xu, Y., & Zhang, T. (2022) · Biopreservation and Biobanking · doi:10.1089/bio.2021.0069
Peripheral blood mononuclear cells cryopreservation and transportation
Prata, K. D. L., & Kondo, A. T. (2022) · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY · doi:10.46765/2675-374x.2022v3n1p158
Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou‐El‐Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P. W., Till, B. G., Bauer, G., & Savoldo, B. (2023) · doi:10.1158/2643-3230.c.6550449
The Science of CAR ‐T Cell Technology
Godby, R. C., Bock, A. M., Kenderian, S. S., & Lin, Y. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch20
CAR-T Cells – Main Steps for Obtaining a Proper “Live Drug” Adoptive Therapy
Neagu, M. T., & Constantin, C. (2024) · South East European Journal of Immunology · doi:10.3889/seejim.2024.6063
Boosting of CAR-T cells with rhabdovirus is limited by type I interferon and rapid contractionPreprint
Burchett, R., Morris, C. G., Ishak, M., Cummings, D. T., Baker, C. L., Marius, R. M., Kazdhan, N., Silvestri, C. M., Bell, J. C., Lichty, B. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.29.626103
Serdyuk, A., Ivanova, N. O., Aleshina, O. A., Dianov, D. V., Kuznetsova, V. S., Mohammad, A., & Васильевна, Б. А. (2025) · Гематология и трансфузиология · doi:10.35754/0234-5730-2025-70-2-208-228
Barriers to Effective Cryopreservation of Cell Therapies: Challenges and Emerging Solution
Hunt, C. J., Johnstone, B. H., & Woods, E. J. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-97297-3_20
Systemtherapien der Zukunft: CAR-T-Zellen
Müller, F., Hoerster, K., & von Tresckow, B. (2026) · Forum · doi:10.1007/s12312-025-01524-z
Manufacturing Cell-Based Products
Lorenzo, N. L., Vilariño, L. B., & Baliu‐Piqué, M. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_28
Dimethyl Sulfoxide (DMSO): A Key Player in Cryopreservation
Aldor, N. L., Peralta, A. C., Iwuji, B., & Poynter, S. J. (2026) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-032-19256-1_7
Scatena, A., Saietz, S., Werner, S. R., Stull, D., & Harrison, C. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102929
Metadata
- Authors
- Panch, S. R., Srivastava, S. K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S. L., Li, X., Dagur, P., Kochenderfer, J. N., Fry, T. J., Mackall, C. L., Lee, D., Shah, N. N., & Stroncek, D. F.
- Affiliations
- National Institutes of Health (US)
- National Heart, Lung, and Blood Institute (US)
- Stanford University (US)
- University of Virginia (US)
- Corresponding author
- Panch, Sandhya R.
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 27
- Issue
- 7
- Pages
- 1275-1285
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC6612799
- OpenAlex
- W2947301297
- Cited by
- 107
- References
- 42
- Citations by year
- 2026: 17 · 2025: 12 · 2024: 16 · 2023: 18 · 2022: 22 · 2021: 12 · 2020: 7 · 2019: 3
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Center for Outcomes Research and Evaluation, Yale School of Medicine
- NIH Clinical Center
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- chimeric antigen receptor T cells, cryopreservation, autologous CAR T-cell therapy, CAR T cell manufacturing, cell viability, apoptosis, mitochondrial dysfunction, cell surface markers, gene expression signatures, CAR T cell persistence
- MeSH terms
- Receptors, Chimeric Antigen, Adolescent, Adult, Aged, Autoantigens, Cell Cycle, Cell Survival, Child, Female, Humans, Male, Middle Aged, Neoplasms, Phenotype, Prospective Studies, Retrospective Studies, T-Lymphocytes, Cryopreservation, Immunotherapy, Adoptive, CD4-CD8 Ratio, Apoptosis, Young Adult, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
